JP2014520856A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520856A5 JP2014520856A5 JP2014520335A JP2014520335A JP2014520856A5 JP 2014520856 A5 JP2014520856 A5 JP 2014520856A5 JP 2014520335 A JP2014520335 A JP 2014520335A JP 2014520335 A JP2014520335 A JP 2014520335A JP 2014520856 A5 JP2014520856 A5 JP 2014520856A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- riluzole
- combination
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507381P | 2011-07-13 | 2011-07-13 | |
| US61/507,381 | 2011-07-13 | ||
| US201161544533P | 2011-10-07 | 2011-10-07 | |
| US61/544,533 | 2011-10-07 | ||
| US201261637759P | 2012-04-24 | 2012-04-24 | |
| US201261637770P | 2012-04-24 | 2012-04-24 | |
| US61/637,759 | 2012-04-24 | ||
| US61/637,770 | 2012-04-24 | ||
| US201261646699P | 2012-05-14 | 2012-05-14 | |
| US61/646,699 | 2012-05-14 | ||
| PCT/US2012/046523 WO2013010015A2 (en) | 2011-07-13 | 2012-07-12 | Combination als therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017090313A Division JP2017128610A (ja) | 2011-07-13 | 2017-04-28 | 併用ａｌｓ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520856A JP2014520856A (ja) | 2014-08-25 |
| JP2014520856A5 true JP2014520856A5 (enExample) | 2015-09-03 |
| JP6145946B2 JP6145946B2 (ja) | 2017-06-14 |
Family
ID=47506929
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520335A Expired - Fee Related JP6145946B2 (ja) | 2011-07-13 | 2012-07-12 | 併用ａｌｓ療法 |
| JP2017090313A Pending JP2017128610A (ja) | 2011-07-13 | 2017-04-28 | 併用ａｌｓ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017090313A Pending JP2017128610A (ja) | 2011-07-13 | 2017-04-28 | 併用ａｌｓ療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10272082B2 (enExample) |
| EP (1) | EP2731611B1 (enExample) |
| JP (2) | JP6145946B2 (enExample) |
| KR (1) | KR101951220B1 (enExample) |
| CN (2) | CN109316480A (enExample) |
| AU (2) | AU2012281042B2 (enExample) |
| BR (1) | BR112014000742A2 (enExample) |
| CA (1) | CA2849213A1 (enExample) |
| EA (2) | EA201791043A1 (enExample) |
| HK (1) | HK1197178A1 (enExample) |
| IL (1) | IL230391B (enExample) |
| IN (1) | IN2014DN00200A (enExample) |
| PH (1) | PH12014500094A1 (enExample) |
| SG (1) | SG10201605707UA (enExample) |
| WO (1) | WO2013010015A2 (enExample) |
| ZA (1) | ZA201400236B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
| DK3137622T3 (da) * | 2014-04-29 | 2022-02-07 | Cytokinetics Inc | Fremgangsmåder til at reducere tilbagegang af vitalkapacitet |
| HUE046869T2 (hu) * | 2014-11-21 | 2020-04-28 | Biohaven Therapeutics Ltd | Riluzol szublingvális formulációja |
| CN107735077A (zh) * | 2014-11-21 | 2018-02-23 | 拜尔哈文制药股份有限公司 | 利鲁唑的舌下给药 |
| EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| US10092564B2 (en) | 2016-03-25 | 2018-10-09 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| US11439626B2 (en) | 2019-09-20 | 2022-09-13 | Icahn School Of Medicine At Mount Sinai | Controlled release formulations of riluzole and their uses |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
| IT1156732B (it) | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
| US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
| US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
| US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
| US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
| JPH0641135A (ja) | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | イミダゾプテリジン誘導体及びその製造方法 |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CN1332743A (zh) | 1998-06-04 | 2002-01-23 | 艾博特公司 | 抑制细胞粘附抗炎化合物 |
| PT1218383E (pt) | 1999-10-08 | 2009-01-29 | Gruenenthal Gmbh | Derivados bicíclicos de imidazo-5-il-amina |
| CA2382919C (en) | 1999-10-08 | 2008-12-09 | Gruenenthal Gmbh | Bicyclic imidazo-3-yl-amine derivatives |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| US20030083318A1 (en) * | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
| US20040235801A1 (en) | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004043913A2 (en) | 2002-11-08 | 2004-05-27 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| ATE461196T1 (de) | 2003-06-26 | 2010-04-15 | Merck Sharp & Dohme | Benzodiazepin-cgrp-rezeptor-antagonisten |
| JP2007521296A (ja) | 2003-07-01 | 2007-08-02 | メルク エンド カムパニー インコーポレーテッド | 高眼圧の治療のための眼科用組成物 |
| JP2007515429A (ja) | 2003-12-19 | 2007-06-14 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | 障害を治療する方法 |
| AU2005208938A1 (en) | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Anti-viral therapeutics |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CN101065016A (zh) | 2004-09-24 | 2007-10-31 | 詹森药业有限公司 | 蛋白激酶的抑制剂咪唑并[4,5－b]吡嗪酮 |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| CA2598489A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
| JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| WO2008016648A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| PT2583970E (pt) | 2006-08-02 | 2016-02-08 | Cytokinetics Inc | Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| CN101522681B (zh) * | 2006-08-02 | 2012-10-03 | 赛特凯恩蒂克公司 | 特定的化学个体、组合物和方法 |
| KR20140104060A (ko) | 2006-10-19 | 2014-08-27 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| EA200900959A1 (ru) | 2007-01-19 | 2010-02-26 | Арди Байосайенсиз, Инк. | Ингибиторы мек |
| EP2139478A4 (en) | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| EP2018854A1 (en) | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| BRPI0907502A2 (pt) | 2008-02-04 | 2019-01-15 | Cytokinetics Inc | pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética |
| US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| CA2730473A1 (en) * | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
| ES2554375T3 (es) | 2008-11-25 | 2015-12-18 | University Of Rochester | Inhibidores de las MLK y métodos de uso |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| CA2765876A1 (en) * | 2009-06-19 | 2010-12-23 | Knopp Neurosciences, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| MX354965B (es) | 2012-04-02 | 2018-03-27 | Cytokinetics Inc | Metodo para mejorar la funcion del diafragma. |
| CN104395458A (zh) | 2012-04-11 | 2015-03-04 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力 |
| DK3137622T3 (da) | 2014-04-29 | 2022-02-07 | Cytokinetics Inc | Fremgangsmåder til at reducere tilbagegang af vitalkapacitet |
-
2012
- 2012-07-12 EA EA201791043A patent/EA201791043A1/ru unknown
- 2012-07-12 IN IN200DEN2014 patent/IN2014DN00200A/en unknown
- 2012-07-12 CN CN201811116043.0A patent/CN109316480A/zh active Pending
- 2012-07-12 EP EP12811325.5A patent/EP2731611B1/en active Active
- 2012-07-12 PH PH1/2014/500094A patent/PH12014500094A1/en unknown
- 2012-07-12 US US14/131,649 patent/US10272082B2/en not_active Expired - Fee Related
- 2012-07-12 JP JP2014520335A patent/JP6145946B2/ja not_active Expired - Fee Related
- 2012-07-12 CA CA2849213A patent/CA2849213A1/en not_active Abandoned
- 2012-07-12 SG SG10201605707UA patent/SG10201605707UA/en unknown
- 2012-07-12 EA EA201490011A patent/EA028060B1/ru not_active IP Right Cessation
- 2012-07-12 BR BR112014000742A patent/BR112014000742A2/pt not_active Application Discontinuation
- 2012-07-12 KR KR1020147000783A patent/KR101951220B1/ko not_active Expired - Fee Related
- 2012-07-12 HK HK14110537.3A patent/HK1197178A1/xx unknown
- 2012-07-12 WO PCT/US2012/046523 patent/WO2013010015A2/en not_active Ceased
- 2012-07-12 CN CN201280034661.5A patent/CN104039148A/zh active Pending
- 2012-07-12 AU AU2012281042A patent/AU2012281042B2/en not_active Ceased
-
2014
- 2014-01-09 IL IL230391A patent/IL230391B/en active IP Right Grant
- 2014-01-10 ZA ZA2014/00236A patent/ZA201400236B/en unknown
-
2016
- 2016-10-13 AU AU2016244263A patent/AU2016244263A1/en not_active Abandoned
-
2017
- 2017-04-28 JP JP2017090313A patent/JP2017128610A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520856A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| JP2014111603A5 (enExample) | ||
| JP2013505205A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| JP2012036225A5 (enExample) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| EA201491484A1 (ru) | Фармацевтические композиции, содержащие диметилфумарат | |
| JP2019524865A5 (enExample) | ||
| JP2013231087A5 (enExample) | ||
| JP2016517883A5 (enExample) | ||
| JP2015083580A5 (enExample) | ||
| JP2017531033A5 (enExample) | ||
| BR112014001297A2 (pt) | procedimento para a fabricação de uma composição farmacêutica em forma de tabletes de liberação prolongada contendo pirfenidona e sua aplicação na regressão da insuficiência renal crônica, na contratura capsular mamária e na fibrose hepática humanas | |
| EA201692388A1 (ru) | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| JP2015510916A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2019530713A5 (enExample) | ||
| AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
| JP2020533296A5 (enExample) | ||
| JP2014507475A5 (enExample) | ||
| JP2014521641A5 (enExample) |